UA121523U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

A method of diagnosing the development of atherosclerosis includes clinical examination, examination of low and high density lipoprotein cholesterol levels, arteriography. Additionally, serum polymorphism of the eNOS T786C gene, pyridinoline, homocysteine, IL-6, PSA and homozygous carrier 786-CC, pyridinolin levels> 8 ng / ml, homocysteine> 20 μmol / l, IL / l, IL / l, IL are determined. l, SRP> 6 mg / l diagnose the development of atherosclerosis.

Description

A useful model belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of cholesterol levels of low and high density lipoproteins, arteriography (Okorokov A.N. Diagnostics of diseases of internal organs. - Vol. 6. - M.: Med. Lit., 2003. - P. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis at the beginning of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that, together with a clinical examination, a study of low and high-density lipoprotein cholesterol levels, arteriography, according to a useful model, polymorphism of the nitric oxide synthase gene (EEMO5) is determined in the patient's blood serum

T786C), the content of pyridinoline, homocysteine, interleukin 6 (IL-6), C-reactive protein (CRP).

With homozygous carrier 786-SS, levels of pyridinoline 28 ng/ml, homocysteine 220 μmol/l,

IL-6 210 ng/l, SRP »6 mg/l diagnose the development of atherosclerosis.

Application of the method. During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. In the patient's blood serum, the polymorphism of the eMmo5 T786C gene is determined, and the content of pyridinoline, homocysteine, IL-6, SRP is determined by the immunoenzymatic method. With homozygous carrier 786-SS, levels of pyridinoline »8 ng/ml, homocysteine 220 μmol/l, IL-6 210 ng/l, SRP »6 mg/l, the development of atherosclerosis is diagnosed.

A specific example of using the method

Patient T., 45 years old, hospitalized in the clinic with a diagnosis of rheumatoid arthritis. Examined

Low and high density lipoprotein cholesterol levels were studied. Arteriography was performed.

There are no signs of atherosclerosis. Polymorphism of the eMO5 T7860 gene was determined in blood serum.

The content of pyridinoline, homocysteine, 1IL-b6, SRP was determined by immunoenzymatic method.

Homozygous carrier 786-SS was established. The levels of pyridinoline - 17.5 ng/ml, homocysteine - 28 μmol/l, 1IL-6-17.2 o ng/l, SRP - 16 mg/l. The development of atherosclerosis was diagnosed.

Arteriographic signs of the process were revealed only after 12 months.

Thus, the proposed method of diagnosis allows establishing a diagnosis at the early stages of the development of the process.

Claims (1)

USEFUL MODEL FORMULA The method of diagnosing the development of atherosclerosis, which includes a clinical examination, a study of low and high-density lipoprotein cholesterol levels, arteriography, which is distinguished by the fact that the polymorphism of the EMO5 T786C gene, the content of pyridinoline, homocysteine, IL-6, SRP and in homozygous carriers are additionally determined in the blood serum 786-SS, levels of pyridinoline »8 ng/ml, homocysteine 220 μmol/l, IL-6 210 ng/l, SRP »6 mg/l diagnose the development of atherosclerosis.